Inhibikase Therapeutics, Inc. (IKT)
NASDAQ: IKT · Real-Time Price · USD
1.740
-0.060 (-3.33%)
At close: Jan 23, 2026, 4:00 PM EST
1.740
0.00 (0.00%)
After-hours: Jan 23, 2026, 5:15 PM EST
Inhibikase Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
16
Market Cap
238.00M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 260.50K | 137.06K | 111.03% |
| Dec 31, 2022 | 123.44K | -2.98M | -96.02% |
| Dec 31, 2021 | 3.10M | 2.40M | 343.92% |
| Dec 31, 2020 | 698.47K | -424.27K | -37.79% |
| Dec 31, 2019 | 1.12M | -2.92M | -72.22% |
| Dec 31, 2018 | 4.04M | 1.98M | 96.07% |
| Dec 31, 2017 | 2.06M | 1.09M | 113.04% |
| Dec 31, 2016 | 967.39K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Coherus Oncology | 277.73M |
| Voyager Therapeutics | 31.32M |
| MediWound | 20.93M |
| Tonix Pharmaceuticals Holding | 10.30M |
| Ovid Therapeutics | 6.61M |
| Orchestra BioMed Holdings | 2.82M |
IKT News
- 2 months ago - Inhibikase Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants - GlobeNewsWire
- 2 months ago - Inhibikase Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants - GlobeNewsWire
- 2 months ago - Inhibikase Therapeutics Advancing IKT-001 to Global Phase 3 Study in Pulmonary Arterial Hypertension - GlobeNewsWire
- 2 months ago - Inhibikase Therapeutics Announces Third Quarter 2025 Financial Results and Highlights Recent Activity - GlobeNewsWire
- 5 months ago - Inhibikase Therapeutics Strengthens Leadership Team with Appointment of Timothy Pigot as Chief Commercial and Strategy Officer - GlobeNewsWire
- 5 months ago - Inhibikase Therapeutics Announces Second Quarter 2025 Financial Results and Highlights Recent Activity - GlobeNewsWire
- 9 months ago - Inhibikase Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Activity - GlobeNewsWire
- 10 months ago - Inhibikase Therapeutics Announces Appointment of David McIntyre as Chief Financial Officer - GlobeNewsWire